Literature DB >> 15969884

Management of hypertension and hypercholesterolaemia in primary care in The Netherlands.

Jacobus T van Wyk1, Gino Picelli, Jeanne P Dieleman, Essy Mozaffari, Piotr Kramarz, Marc A M van Wijk, Johan van der Lei, Miriam C J M Sturkenboom.   

Abstract

OBJECTIVE: Screening, treatment and monitoring guidelines for hypertension and hypercholesterolaemia have been developed to assist physicians in providing evidence-based health care. We conducted a retrospective study to assess the management of patients with these single or combined conditions. RESEARCH DESIGN AND METHODS: This was a retrospective cohort study conducted using data from the Integrated Primary Care Information (IPCI) project based in The Netherlands. Management of hypertension and hypercholesterolaemia was assessed from 2000-2003 by measuring the numbers of patients screened for these conditions, treated pharmacologically and monitored for treatment success.
RESULTS: Approximately 11%, 3% and 10% of participants were eligible for screening for hypertension alone, hypercholesterolaemia alone and both conditions, respectively. Blood pressure screening was high in patients eligible for both blood pressure and cholesterol screening (> 86%), whereas cholesterol screening was low (< 56%). Among patients newly identified with hypertension or hypercholesterolaemia who were eligible for pharmacotherapy, 29% and 43% respectively were not treated within one year of diagnosis. Undertreatment was significantly lower in patients with both conditions (24% and 37% for antihypertensive and lipid-lowering treatment, respectively and 28% were not treated for both). Among newly treated patients, in the first year of treatment there was no record of a blood pressure or cholesterol assessment, for 35% and 72%, respectively.
CONCLUSION: Management was sub-optimal in patients with hypertension or hypercholesterolaemia as well as in those with both of these conditions. The results of this study are likely to be widely applicable, particularly to other European and industrialised countries that have similar free-access health care systems to The Netherlands.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15969884     DOI: 10.1185/030079905X46368

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  8 in total

1.  Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom.

Authors:  Thomas M MacDonald; Steven V Morant
Journal:  Br J Clin Pharmacol       Date:  2008-02-14       Impact factor: 4.335

2.  Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study.

Authors:  Pearl D Gumbs; W M Monique Verschuren; Aukje K Mantel-Teeuwisse; Ardine G de Wit; Albert Hofman; Paul H Trienekens; Bruno H Ch Stricker; Antonius de Boer; Olaf H Klungel
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999).

Authors:  Aukje K Mantel-Teeuwisse; Olaf H Klungel; Albert Hofman; W M Monique Verschuren; Paul H Trienekens; Arijan J Porsius; Bruno H Ch Stricker; Anthonius de Boer
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

Review 4.  Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection.

Authors:  Domenico Galzerano; Cristina Capogrosso; Sara Di Michele; Emanuele Bobbio; Paola Paparello; Carlo Gaudio
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

5.  Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.

Authors:  Franz H Messerli; George L Bakris; David Ferrera; Mark C Houston; Robert J Petrella; John M Flack; William Sun; EunMee Lee; Joel M Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-08       Impact factor: 3.738

6.  Targeted case finding in the prevention of cardiovascular disease: a stepped wedge cluster randomised controlled trial.

Authors:  Karla Hemming; Ronan Ryan; Paramjit Gill; Paul Westerby; Kate Jolly; Tom Marshall
Journal:  Br J Gen Pract       Date:  2016-08-15       Impact factor: 5.386

7.  Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998-2004: a longitudinal observational study.

Authors:  Jacoba P Greving; Petra Denig; Dick de Zeeuw; Henk J G Bilo; Flora M Haaijer-Ruskamp
Journal:  Cardiovasc Diabetol       Date:  2007-09-20       Impact factor: 9.951

8.  Trends in polypharmacy and dispensed drugs among adults in the Netherlands as compared to the United States.

Authors:  Monika P Oktora; Petra Denig; Jens H J Bos; Catharina C M Schuiling-Veninga; Eelko Hak
Journal:  PLoS One       Date:  2019-03-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.